Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 7/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | UGCG | Q16739 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104170 | 0.83 | CRHR1 (0.39) | CRHR1CYP11B1CYP11B2ARTRPV4 | |
| SCHEMBL5100862 | 0.83 | CRHR1 (0.37) | CRHR1CYP11B1CYP11B2ARTRPV4 | |
| SCHEMBL5103863 | 0.78 | TTR (0.43) | KDM4ESMN1; SMN2OPRM1ARUGCG | |
| SCHEMBL6936302 | 0.72 | AR (0.42) | CRHR1CYP11B1CYP11B2ARTRPV4 | |
| SCHEMBL5101089 | 0.69 | CYP11B2 (0.43) | CRHR1CYP11B1CYP11B2ARTRPV4 | |
| SCHEMBL22044256 | 0.69 | CRHR1 (0.38) | CRHR1KDM4EARTRPV4 | |
| SCHEMBL4240070 | 0.69 | AR (0.74) | CRHR1AR | |
| SCHEMBL3532873 | 0.69 | NOTUM (0.48) | KDM4EARTRPV4 | |
| SCHEMBL250177 | 0.67 | NOTUM (0.47) | ARTRPV4 | |
| SCHEMBL409405 | 0.67 | TRPV4 (0.53) | ARTRPV4ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370540-A1 | ANTI-THROMBOTIC CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-05 | — | — | US | disclosed |
| WO-2002072558-A1 | ANTI-THROMBOTIC CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | SERPINC1, TFPI, F2 | CRHR1 4282/4885KDM4E 1448/4885SMN1; SMN2 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.